Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1272 • ACR Convergence 2021
Characterizing Patient and Physician Perceptions of Systemic Lupus Erythematosus (SLE) Disease Burden Using Traditional Rheumatoid Arthritis Outcomes Measures
Christopher Bell¹, Shirley Huang¹, Meg Wang², Maral DerSarkissian², Mei Sheng Duh², Bhavna Dhillon³, Carlyne Averell¹, Bernie Rubin¹ and Daniel Wallace⁴, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Analysis Group, Boston, MA, ³United Rheumatology, Hauppauge, NY, ⁴Cedars-Sinai, Los Angeles, CA
Background/Purpose: SLE is a chronic, autoimmune disease affecting multiple organ systems, and characterized by fluctuating disease activity. Many SLE disease measures may be impractical for…
Abstract Number: 1288 • ACR Convergence 2021
First Year Infection Risk in SLE Patients Treated with Rituximab versus Standard of Care Treatment: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Mia Rodziewicz¹, Sarah Dyball¹, Stephen McDonald¹, Emily Sutton¹, Ben Parker¹, The British Isles Lupus Assessment Group² and Ian N. Bruce¹, ¹University of Manchester, Manchester, United Kingdom, ²Lupus Trust, London
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have an increased risk of infection compared to the general population. We aimed to assess the early risk…
Abstract Number: 1420 • ACR Convergence 2021
Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus
Peter Izmirly¹, Mimi Kim², Marie Samanovic-Golden³, Ruth Fernandez Ruiz⁴, Sharon Ohana³, Alexis Engel⁵, Kristina Deonaraine¹, Mala Masson⁴, Xianhong Xie⁶, Amber Cornelius⁴, Ramin Herati⁴, Rebecca Haberman⁴, Jose Scher¹, Allison Guttmann³, Rebecca Blank⁷, Ben Plotz³, Mayce Haj-Ali⁴, Brittany Banbury³, Sara Stream⁸, Ghadeer Hasan³, Gary Ho³, Paula Rackoff⁷, Ashira Blazer³, H. Michael Belmont³, Amit Saxena³, Mark Mulligan⁴, Robert Clancy⁴ and Jill Buyon³, ¹New York University School of Medicine, New York, NY, ²Albert Einstein College of Medicine, Larchmont, NY, ³NYU School of Medicine, New York, NY, ⁴NYU Grossman School of Medicine, New York, NY, ⁵NYU Langone Health, New Yok, NY, ⁶Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, NY, ⁷New York University, New York, NY, ⁸NYU Langone Health, New York, NY
Background/Purpose: Since the Phase 3 clinical studies of all three COVID-19 vaccines excluded patients on immunosuppressants or immune-modifying drugs within 6 months of enrollment, data…
Abstract Number: 1467 • ACR Convergence 2021
Determinants of Cervical Cancer Screening Patterns Among Women with Systemic Lupus Erythematosus
Sarah Chung¹, Kimiko Oshima¹, Jenna Thomason¹, Michael Singleton¹ and Namrata Singh², ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA
Background/Purpose: Women with systemic lupus erythematosus (SLE) are vulnerable to cervical dysplasia. This is due to the persistence of human papillomavirus (HPV) related to immunosuppression…
Abstract Number: 1499 • ACR Convergence 2021
Imbalance Between T Follicular Cells and T Regulatory Cells Involved in High Fat-Diet Associated Lupus Development in MRL/lpr Mice
Ronak Patel¹, Therese Posas-Mendoza², Juan Meng³, Xuhua Shi³, Swathi Dhulipala⁴, Chad Hille², Linh Hellmers¹, Robert Quinet⁵, William Davis⁶, Jerald Zakem⁷, Chandana Keshavamurthy¹, Zongbing You³ and Xin Zhang¹, ¹Ochsner, New Orleans, LA, ²Ochsner Clinic Foundation, New Orleans, LA, ³Tulane University, New Orleans, LA, ⁴Ochsner Clinic Foundation, River Ridge, LA, ⁵Ochsner Health, River Ridge, LA, ⁶Ochsner Medical Center, New Orleans, LA, ⁷Ochsner Health Systems, Metairie, LA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by persistent inflammation and production of autoantibodies, which deposit within numerous tissues leading to…
Abstract Number: 1637 • ACR Convergence 2021
Covid-19 Infection Among Pediatric Rheumatology Patients: A Single Center Experience
Eric Kok, Martha Curry, Andrea Ramirez, Eyal Muscal and Marietta DeGuzman, Baylor College of Medicine, Houston, TX
Background/Purpose: Infection with novel coronavirus (COVID-19) in children, unlike adults, is generally asymptomatic or causes mild disease although some may develop severe illness. In particular,…
Abstract Number: 1740 • ACR Convergence 2021
Efficacy of Anifrolumab in Patients with SLE Previously Treated with Biologics: Post Hoc Analysis of Data from 2 Phase 3 Trials
Richard Furie¹, Eric Morand², Kenneth Kalunian³, Konstantina Psachoulia⁴, Emmanuelle Maho⁵, Catharina Lindholm⁶ and Raj Tummala⁴, ¹Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ²Monash University, Melbourne, Australia, ³University of California, La Jolla, CA, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 We investigated…
Abstract Number: 1758 • ACR Convergence 2021
WITHDRAWN
Abstract Number: 1929 • ACR Convergence 2021
Metabolomics Identifies Early Mechanisms of Atherogenic Dyslipidaemia in Juvenile-SLE Patients Associated with Inflammation
George Robinson¹, Kirsty Waddington¹, Junjie Peng¹, Anna Radziszewska¹, David Isenberg², Yiannis Ioannou¹, Ines Pineda-Torra¹, Coziana Ciurtin¹ and Elizabeth Jury¹, ¹University College London, London, United Kingdom, ²Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of mortality in patients with juvenile-onset systemic lupus erythematosus (JSLE) through atherosclerosis, the build-up of lipids and…
Abstract Number: 0164 • ACR Convergence 2021
Disrupted Executive Control Network Structural-Functional Integration Is Associated with Inferior Performance of Cognitive Switching Tasks in Patients with Systemic Lupus Erythematosus (SLE)
Xing Qian¹, Danielle S Bassett², Kwun Kei Ng¹, Beatrice RY Loo¹, Amelia J Koh¹, Juan Helen Zhou¹ and Anselm Mak³, ¹Center for Sleep and Cognition, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Departments of Physics & Astronomy, Bioengineering, Electrical & Systems Engineering, Neurology, and Psychiatry, University of Pennsylvania, Philadelphia, PA, ³National University of Singapore, Singapore, Singapore
Background/Purpose: Cognitive flexibility, a process that enables goal-oriented cognitive switching between mental function modes, is central to executive function which is impaired in SLE patients.…
Abstract Number: 0335 • ACR Convergence 2021
Performances of Different Classification Criteria for Systemic Lupus Erythematosus in a Single Center Cohort from Turkey
Ege Sinan Torun¹, Erdem Bektaş¹, Fatih Kemik², Murat Bektaş³, Cigdem Cetin⁴, Yasemin Yalcinkaya⁴, Bahar Esen⁴, Ahmet Gül⁵ and Murat Inanc⁶, ¹Istanbul University Istanbul Faculty of Medicine, İstanbul, Turkey, ²Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, ³Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁵Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁶Istanbul University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Recently developed EULAR/ACR classification criteria for systemic lupus erythematosus (SLE) has important differences compared to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) SLE…
Abstract Number: 0354 • ACR Convergence 2021
A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
Kathryn Starzyk¹, Gary Curhan² and Julia Brault², ¹OM1, Inc, Boston, MA, ²OM1, Boston, MA
Background/Purpose: Features of autoimmune conditions may coexist in individual patients, which may represent an overlapping single disease with features of both (i.e., ‘rhupus’), or the…
Abstract Number: 0537 • ACR Convergence 2021
The Clinical, Oral Small Molecule IRAK4 Inhibitor, GS-5718, Improves Survival and Reduces Disease Pathologies by Modulating Multiple Inflammatory Endpoints in the Murine NZB/W Model of Spontaneous Lupus
Adam Yadon¹, Vanessa Gorney², Angie Hammond³, Ethan Grant² and Astrid Clarke³, ¹Gilead Sciences, Inc., Seattle, WA, ²Gilead Sciences, Inc, Foster City, CA, ³Gilead Sciences, Inc, Seattle, WA
Background/Purpose: Lupus is a heterogenous autoimmune disease characterized by loss of immune tolerance, production of nucleic acid:autoantibody immune complexes, immune cell hyperactivation, and increased proinflammatory…
Abstract Number: 0628 • ACR Convergence 2021
Higher Quality of Care for Patients with Systemic Lupus Erythematosus in a Subspecialty Lupus Clinic: A Multi-Setting Cross-Sectional Study
Sidha Sreedharan¹, Ning Li¹, Geoffrey Littlejohn¹, Russell Buchanan², Mandana Nikpour³, Eric Morand⁴, Alberta Hoi⁵ and Vera Golder⁶, ¹Monash University, Melbourne, Australia, ²Austin Health, Heidelberg, Melbourne, Australia, ³University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁴School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ⁵Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ⁶Monash University, Clayton, Australia
Background/Purpose: Healthcare quality for systemic lupus erythematosus (SLE) is a modifiable target for improving patient outcomes. Disease-specific subspecialty lupus clinics may offer experienced healthcare professionals,…
Abstract Number: 0859 • ACR Convergence 2021
Evaluation of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Dysfunction in Systemic Lupus Erythematosus
Sudha Raghunath¹, Yifat Glikmann-Johnston¹, Eric Morand², Julie Stout¹ and Alberta Hoi³, ¹Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ³Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Background/Purpose: Cognitive dysfunction (CD) affects approximately 40% of SLE patients (1), impacting on employment, daily function, and quality of life (2)(3). Diagnostic neuropsychological testing is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].